Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLI.e

ARDS - Acute lung injury

Following withdrawal of the drug, a condition known as the 'Ruxolitinib Withdrawal Syndrome'. See Xa

Publications

Herman DD, Kempe CB, Thomson CC, McCallister JW

Recurrent hypoxemic respiratory failure. Beyond the usual suspects.

Annals of the American Thoracic Society 2014 Sep;11;1145-8 — 2014 Sep — 1145-8

Beauverd Y, Samii K

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.

International journal of hematology 2014 Nov;100;498-501 — 2014 Nov — 498-501